Novartis on Wednesday won a new European approval for its inflammation drug Cosentyx in a form of arthritis, as the Swiss drugmaker predicts broadening use of its top-selling medicine will eventually push annual sales beyond $5 billion.
European Commission approved Cosentyx for adult patients with active non-radiographic axial spondyloarthritis , characterized by chronic back pain. This is the fourth indication for Cosentyx, in addition to its uses to treat psoriasis, psoriatic arthritis and ankylosing spondylitis.
“We’re confident that this brand will continue on its trend to exceed $5 billion,” Chief Executive Vas Narasimhan said on Tuesday in an analyst call, after Cosentyx’s first-quarter sales hit $930 million.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novartis posts first-quarter sales, profit beat as COVID-19 spurs prescriptionsSwiss drugmaker Novartis reported rising first-quarter sales and profit that beat analyst expectations and confirmed its 2020 targets as the coronavirus pandemic prompted patients to stock up on their prescriptions in advance.
Read more »
Cloudflare expands its cybersecurity business in China with JD.com - Business Insider$7 billion Cloudflare will expand into 150 new data centers in China, making a big bet on the country's internet economy amid a global downturn
Read more »
Australia's Westpac sees over $2 billion hit to earnings amid virusWestpac Banking Corp said it would write down more than A$3.67 billion ($2.36 billion) in its first-half results, with most of the charges stemming from the economic deterioration expected from the coronavirus outbreak.
Read more »
Imperial's premium cigar era draws to a close in $1.33 billion saleImperial Brands is withdrawing from the premium cigar business to focus on vaping, with a 1.23 billion euro ($1.33 billion) sale of hand-rolled makes including Cohiba and Montecristo which will help it pay down debt.
Read more »
Imperial's premium cigar era draws to $1.33 billion end after slow burn saleImperial Brands is withdrawing from the premium cigar business to focus on vaping, with a 1.23 billion euro ($1.33 billion) sale of hand-rolled makes including Cohiba and Montecristo which will help it pay down debt.
Read more »
Merck sees $2.1 billion hit to full-year sales from coronavirus pandemicMerck & Co Inc warned of a $2.1 billion hit to its 2020 revenue on Tuesday as social distancing due to the COVID-19 pandemic is expected to hammer sales of medically administered drugs including its blockbuster Keytruda treatment.
Read more »